It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%.” - The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, March ...
The EMA's human medicines advisory committee has recommended that BioMarin Pharmaceutical's haemophilia A gene therapy Roctavian be approved in the EU, removing one of the last barriers to launch.
In their sights is first-to-market Roctavian (valoctocogene roxaparvovec) from BioMarin, which was approved in Europe in 2022 and the US last year, but has seen glacial sales growth, coming in at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback